Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Mitochondrial RNA Methylation By METTL17 Rewires Metabolism and Regulates Retrograde Mitochondrial-Nuclear Communication in AML

Blood (2024) 144 (Supplement 1): 625.

https://doi.org/10.1182/blood-2024-201916

Published: 2024

Journal Articles

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine Zain

Blood (2024) 144 (Supplement 1): 468.

https://doi.org/10.1182/blood-2024-205617

Published: 2024

Journal Articles

The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

Myo Htut, Keehoon Lee, Nitya Nathwani, Michael Rosenzweig, Murali Janakiram, Scott R. Goldsmith, James F. Sanchez, Martha Scott, Jonathan Keats, Amrita Y Krishnan, Steven T. Rosen, Sophia S. Wang

Blood (2024) 144 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2024-206314

Published: 2024

Journal Articles

HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

Blood (2024) 144 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2024-206279

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Blood (2024) 144 (Supplement 1): 3638.

https://doi.org/10.1182/blood-2024-206590

Published: 2024

Journal Articles

Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter's Transformation

Prajish Iyer, Brian Jiang, Girish Venkataraman, Joo Y. Song, Wing Chung Chan, Tanya Siddiqi, Steven T. Rosen, Alexey Danilov, Antje Gohla, Lili Wang

Blood (2024) 144 (Supplement 1): 760.

https://doi.org/10.1182/blood-2024-199843

Published: 2024

Journal Articles

Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

Li Du, Jiamin Guo, Zhenhua Chen, Jianjun Chen, Guido Marcucci, Steven T. Rosen

Blood (2023) 142 (Supplement 1): 411.

https://doi.org/10.1182/blood-2023-178037

Published: 2023

Journal Articles

Glycerolipid Metabolism Via the MGA-MYC-NME1-PGP Axis As a Key Regulator of Oxidative Phosphorylation in Richter's Transformation

Prajish Iyer, Brian Jiang, Girish Venkataraman, Joo Y Song, Tanya Siddiqi, Steven T. Rosen, Alexey Danilov, Lili Wang

Blood (2023) 142 (Supplement 1): 79.

https://doi.org/10.1182/blood-2023-179427

Published: 2023

Journal Articles

The Role of Macrophage Migration Inhibitory Factor (MIF) in Regulation of T-Cell Activity in Multiple Myeloma

Metin Gunes, Steven T. Rosen, Emine Gulsen Gunes

Blood (2023) 142 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2023-180085

Published: 2023

Journal Articles

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

John H. Baird, Marissa Morales Del Real, Joo Y. Song, Geoffrey P. Shouse, Alexey Danilov, Alex F. Herrera, Leslie L. Popplewell, Steven T. Rosen, Jennifer Davis, Baishakhi Barva, Lu Chen, Larry W. Kwak, Stephen J. Forman, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 4840.

https://doi.org/10.1182/blood-2023-182456

Published: 2023

Journal Articles

CD84 (SLAMF5) As a Potential Target for Immunomodulation in Cutaneous T-Cell Lymphoma (CTCL)

Metin Gunes, Steven T. Rosen, Emine Gulsen Gunes

Blood (2023) 142 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2023-184362

Published: 2023

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (25): 2697–2708.

https://doi.org/10.1182/blood.2022016624

Published: 2022

Includes: Supplemental data

Journal Articles

A Novel Approach to Achieve Long-Lasting Antitumor Immunity in Multiple Myeloma

Metin Gunes, Jessica Dang, Yate-Ching Yuan, Idit Shachar, Murali Janakiram, Mingye Feng, Steven T. Rosen, Emine Gulsen Gunes

Blood (2022) 140 (Supplement 1): 7092–7093.

https://doi.org/10.1182/blood-2022-167036

Published: 2022

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (19): 2024–2036.

https://doi.org/10.1182/blood.2022016747

Published: 2022

Includes: Supplemental data

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Xu Cao, Yingyu Wang, Wencan Zhang, Xiancai Zhong, E. Gulsen Gunes, Jessica Dang, Jinhui Wang, Alan L. Epstein, Christiane Querfeld, Zuoming Sun, Steven T. Rosen, Mingye Feng

Blood (2022) 139 (22): 3290–3302.

https://doi.org/10.1182/blood.2021013901

Published: 2022

Includes: Supplemental data

NARROW

Mitochondrial RNA Methylation By METTL17 Rewires Metabolism and Regulates Retrograde Mitochondrial-Nuclear Communication in AML

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter's Transformation

Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

Glycerolipid Metabolism Via the MGA-MYC-NME1-PGP Axis As a Key Regulator of Oxidative Phosphorylation in Richter's Transformation

The Role of Macrophage Migration Inhibitory Factor (MIF) in Regulation of T-Cell Activity in Multiple Myeloma

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

CD84 (SLAMF5) As a Potential Target for Immunomodulation in Cutaneous T-Cell Lymphoma (CTCL)

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

A Novel Approach to Achieve Long-Lasting Antitumor Immunity in Multiple Myeloma

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only